Health and Medicine
Vanderbilt University Medical Center’s Crowe receives 2020 “Golden Goose” Award for COVID-19 research
Dec. 1, 2020—James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award.
Hot spots identified for colorectal cancer mortality rates among young women
Nov. 23, 2020—Women diagnosed with early-onset colorectal cancer have a greater risk of dying from the disease depending upon their county of residence, according to a study published in Clinical and Translational Gastroenterology.
A cohort for type 2 diabetes studies
Nov. 17, 2020—A study group of more than 600,000 patients with type 2 diabetes, identified from electronic medical records in the PCORnet national research network, could be valuable for assessing the safety of type 2 diabetes drugs.
Imaging “biomarker” for Alzheimer’s disease progression
Nov. 16, 2020—Changes in connectivity in the brain’s white matter may be a novel neuroimaging biomarker for assessing Alzheimer’s disease progression.
New therapeutic target for lung cancer
Nov. 12, 2020—Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer.
Breast cancer treatment in older women
Nov. 12, 2020—A new study from Vanderbilt epidemiologists suggests that it’s time to reconsider clinical practice guidelines for the treatment of early-stage breast cancer in older women.
Study underscores importance of personalized medicine in kidney cancer
Nov. 10, 2020—A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.
Hydroxychloroquine does not help patients hospitalized with COVID-19: Study
Nov. 9, 2020—Findings from a national study published Nov. 9 in the Journal of the American Medical Association (JAMA) “do not support” the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19, the report concludes.
HCQ doesn’t protect health workers from COVID: study
Nov. 5, 2020—Hydroxychloroquine (HCQ) did not significantly reduce the incidence of COVID-19 among health care workers who participated in a national study that included Vanderbilt University Medical Center.
New treatment for a rare obesity
Nov. 3, 2020—Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity.
VUMC begins study of second COVID-19 vaccine
Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
Frog peptides as anti-HIV microbicides
Nov. 2, 2020—Peptides derived from the antimicrobial peptides secreted by frogs could function as microbicides to limit HIV transmission, while sparing protective vaginal bacteria.
